GLEN ALLEN, VA / ACCESSWIRE / February 25, 2019 / Exactus Inc.
(OTCQB: EXDI),a healthcare company pursuing
opportunities in hemp-derived, cannabidiol (CBD) products and point
of care diagnostics, launched its first product and is pleased to
announce the company has received its first purchase
order.

The company launched a 750mg full spectrum advanced absorption
tincture and received its first purchase order from a customer in
the health and nutritional medical space, a market vertical the
company is currently focusing on building out and one that Hemp
Business Journal,estimates will be the
fastest growing market in the hemp-derived CDB space over the next
four years.

Philip Young, CEO of Exactus said, “We are in the early
stages of transitioning into a leader in the CBD market sector. The
rapid transition to commercialization with our first product launch
and our initial purchase order
is evidence that we have teamed up with the perfect partner,
Ceed2Med. This is the first of many products that we currently have
in our pipeline and expect to begin selling in the near future. The
quality of our product and the science behind the grow, farming,
and processing of our hemp sets us apart from and above
competitors. We look forward to building relationships with an
array of additional healthcare practitioners, wholesalers, and
retailers. While attending the 15thAnnual PDS Conference this past week
in Orlando, Florida we met with representatives from several
thousand independent pharmacies who provided strong confirmation
that our plan to provision pharmacies with FDA food-grade CBD
products manufactured to cGMP standards is being sought out by
pharmacy owners and pharmacists alike. Over the next several weeks
we expect to schedule meetings with pharmacy groups to initiate
sales. We look to set the industry standards on transparency and
quality with every product. Our products feature a unique, readable
QR code that traces the product from seed/strain/farm/plot to
finished good, accompanied by a 3rd party laboratory Certificate of
Analysis and Material Safety Data Sheet that should be well
received by pharmacists and medical professionals alike when
recommending CBD products.”

For information about our products and availability please call
804-205-5036 or email,ir@exactusinc.com.

About
Exactus:

Exactus, Inc., is
a healthcare
company pursuing
opportunities in two distinct business segments, Hemp
derived, Cannabidiol,
which is more commonly referred to as CBD. Industrial hemp is a
type of cannabis, defined by the federal government as having THC
(tetrahydrocannabinol) content of 0.3 percent or less. That amount
has not been shown to make a person feel "high."THC is the psychoactive compound found
in cannabis.The company is
also developing point of care diagnostics. For more information
about Exactus:www.exactusinc.com.

Investor Notice

Investing in our securities involves a high degree of risk. Before
making an investment decision, you should carefully consider the
risks, uncertainties and forward-looking statements described under
"Risk Factors" in Item 1A of our most recent Form 10-K for the
fiscal year ended December 31, 2017 filed with the Securities and
Exchange Commission (the "SEC") on April 2, 2018 and under the
heading “Risk Factors” in our Current Report on Form
8-K filed with the SEC on January 14, 2019, and in other periodic
and current reports we file with the SEC. If any of these
risks were to occur, our business, financial condition or results
of operations would likely suffer. In that event, the value of our
securities could decline, and you could lose part or all of your
investment. The risks and uncertainties we describe are not the
only ones facing us. Additional risks not presently known to us or
that we currently deem immaterial may also impair our business
operations. In addition, our past financial performance may not be
a reliable indicator of future performance, and historical trends
should not be used to anticipate results in the future. See "Safe
Harbor" below.

Safe Harbor - Forward Looking Statements

The information provided in this press release may include
forward-looking statements relating to future events or the future
financial performance of the Company. Because such statements are
subject to risks and uncertainties, actual results may differ
materially from those expressed or implied by such forward-looking
statements. Words such as "anticipates," "plans," "expects,"
"intends," "will," "potential," "hope" and similar expressions are
intended to identify forward-looking statements. These
forward-looking statements are based upon current expectations of
the Company and involve assumptions that may never materialize or
may prove to be incorrect. Actual results and the timing of events
could differ materially from those anticipated in such
forward-looking statements as a result of various risks and
uncertainties. Detailed information regarding factors that may
cause actual results to differ materially from the results
expressed or implied by statements in this press release relating
to the Company may be found in the Company's periodic and current
filings with the SEC, including the factors described in the
sections entitled "Risk Factors", copies of which may be obtained
from the SEC's website at www.sec.gov. The Company does not
undertake any obligation to update forward-looking statements
contained in this press release.